SPDL1 and pancreatic neoplasm: (36) prospectively included 60 patients with pancreatic cancer and indicated that, by multivariate analysis, patients with high levels of sPD-L1 had worse OS compared to those patients with low levels of sPD-L1 (HR, 3.249; p=0.012; median OS, 8.4 vs. 10.2 months).